Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report

Omalizumab is approved for the treatment of chronic severe persistent asthma. As a trigger for anaphylaxis, the frequency of subcutaneous specific immunotherapy (SCIT) is high. We report the case of a 11-year-old boy with severe allergic asthma. During the initial phase of immunotherapy he experienc...

Descripción completa

Detalles Bibliográficos
Autores principales: Stelmach, Iwona, Sztafińska, Anna, Woicka-Kolejwa, Katarzyna, Jerzyńska, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112270/
https://www.ncbi.nlm.nih.gov/pubmed/25097493
http://dx.doi.org/10.5114/pdia.2014.43192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112270/
https://www.ncbi.nlm.nih.gov/pubmed/25097493
http://dx.doi.org/10.5114/pdia.2014.43192

Ejemplares similares